This refresh
Data-driven refresh June 24, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5222-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2558 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. INCY — Incyte Corporation · score 90.5
Biotechnology · price $108.46 · 1Y $110.26 · 5Y $161.43 · 10Y $239.47
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 15.3x A- · PEG 0.36 A
Why now. Incyte Corporation is a compelling growth story driven by its robust product lineup, including JAKAFI and ICLUSIG, with a 21.2% revenue growth rate and a $1.4b free cash flow, all while maintaining a 15.3 P/E ratio and a 0.36 PEG ratio, suggesting the company's growth is not only strong but also reasonably valued, and it all rests on the continued success of its commercialized therapeutics like JAKAFI for myelofibrosis treatment.
Moat. Incyte's durable edge comes from its portfolio of commercialized and pipeline assets, particularly its kinase inhibitors like ICLUSIG, which provide a high barrier to entry due to their complexity and the company's expertise in their development, further supported by a 25.5% ROE, indicating pricing power from category leadership in specific therapeutic areas.
Risk. The bear case against Incyte Corporation centers around the potential for increased competition in the biopharmaceutical space, particularly from generic versions of its drugs or new treatments for conditions like myelofibrosis and chronic myeloid leukemia, which could erode its 26.7% profit margin, and with a 0.79 beta, the stock's volatility could increase if the broader market declines, a concrete signal that would confirm the bear case is a significant decline in sales of its flagship drugs like JAKAFI.
Horizon. 1-3 yr $110.26 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $161.43 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $239.47 if current growth sustains into durable earnings power.
2. DOCS — Doximity, Inc. · score 90.1
Health Information Services · price $20.83 · 1Y $25.42 · 5Y $37.22 · 10Y $55.21
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 21.3x B+ · PEG 0.59 A-
Why now. Doximity's durable growth trajectory, driven by its personalized newsfeed and workflow tools like Ask and Scribe, positions the company for long-term compounding, with a PEG ratio of 0.59, revenue growth of 13.1%, and profit margin of 30.4%, all of which suggest that the company's growth is not only strong but also efficiently priced, resting on the crux of whether it can maintain this balance of growth and profitability.
Moat. Doximity's moat is rooted in its ability to provide a unique platform for medical professionals, combining clinical content, professional updates, and workflow tools in a HIPAA-compliant environment, which creates a network effect that enhances the value proposition for its members, thereby protecting its 20.6% ROE through pricing power derived from its category leadership in medical professional networking and information sharing.
Risk. The bear case against Doximity centers on the potential for decelerating growth, heightened competition, or margin compression, concerns that are somewhat mitigated by the company's debt-to-equity ratio of 0.01 but are still vulnerable to the beta of 1.29, indicating higher volatility, and the risk that the analyst consensus target of $25.42 may not be achievable if growth slows or if the company fails to execute on its strategic initiatives, with a concrete signal of trouble being a significant decline in revenue growth or a failure to expand its user base.
Horizon. 1-3 yr $25.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.22 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $55.21 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.9
Software - Application · price $262.24 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.0x A- · PEG 0.67 A-
Why now. The bull case for INTU rests on its ability to compound growth through its QuickBooks services and Mailchimp marketing automation, with a 15.6% revenue growth rate and a 21.9% profit margin, driven by its $7.8B in free cash flow, which persists due to its strong positioning in the small and mid-market business segment.
Moat. INTU's durable edge comes from its pricing power in the QuickBooks and Mailchimp platforms, driven by its 22.2% return on equity, which is a result of its category leadership in financial and business management online services, making it difficult for competitors to quickly replicate its offerings.
Risk. The bear case against INTU is centered around its 0.96 beta and 16 P/E ratio, which may indicate a potential correction in the stock price, and the company's 0.33 debt-to-equity ratio, which, although relatively low, could still pose a risk if interest rates rise, confirming the bear case if the company's revenue growth decelerates significantly.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89.8
Software - Application · price $196.57 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.3x A · PEG 0.53 A-
Why now. The bull case for ADBE rests on its ability to compound growth through its Digital Media segment, which serves a wide range of customers from photographers to knowledge workers, with a profit margin of 28.7% and revenue growth of 10.5%. This, combined with a PEG ratio of 0.53, indicates that the growth is not only strong but also reasonably priced. The crux of this thesis is the persistence of this growth, driven by the demand for content creation and management tools.
Moat. Adobe's durable edge comes from its integrated platform in the Digital Experience segment, which enables brands and businesses to manage customer experiences from analytics to commerce. This, coupled with its high ROE of 62.8%, driven by pricing power from category leadership in digital media and experience, makes it difficult for competitors to quickly replicate. The switching costs for customers are also high, given the breadth of tools and services Adobe offers.
Risk. The bear case against ADBE is centered around its debt to equity ratio of 0.61 and a beta of 1.4, indicating a potential volatility in its stock price. Additionally, with a PE TTM of 11.3, there's a risk that the stock might be overvalued if growth decelerates. A concrete signal that would confirm the bear case is a significant decline in revenue growth or a failure to maintain its profit margins, which would undermine the bull thesis of persistent growth.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
5. LRN — Stride, Inc. · score 89.4
Education & Training Services · price $84.81 · 1Y $97.53 · 5Y $142.80 · 10Y $211.83
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.3x A- · PEG 0.46 A
Why now. The bull case for LRN rests on its ability to compound growth through its proprietary online curriculum and software systems, with a 17.9% revenue growth rate and a 13.3 P/E ratio, all while maintaining a 12.2% profit margin. This growth is driven by its technology-based products and services that enable clients to support individualized learning for students. The crux of this thesis is that LRN can continue to leverage its integrated package of systems, services, and products to drive growth in the virtual and blended public school market.
Moat. LRN's durable edge is its ability to provide a comprehensive and individualized learning experience through its technology-based products and services, which creates a high switching cost for its clients. This is evident in its 18.8% ROE, which is driven by its pricing power and category leadership in the online curriculum and software systems market. Additionally, its 0.33 debt-to-equity ratio provides a stable financial foundation to support its growth initiatives.
Risk. The bear case for LRN is that its growth may be hindered by increased competition in the online education market, which could lead to a contraction in its 12.2% profit margin. Furthermore, its 0.08 beta indicates a low volatility, but a potential downturn in the education sector could still impact its stock price. A concrete signal that would confirm the bear case is a decline in its revenue growth rate, which would break the bull thesis.
Horizon. 1-3 yr $97.53 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $142.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $211.83 if current growth sustains into durable earnings power.
6. PCTY — Paylocity Holding Corporation · score 89.3
Software - Application · price $103.79 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 22.2x B+ · PEG 0.78 A-
Why now. The bull case for Paylocity Holding Corporation rests on its ability to compound growth through its cloud-based human capital management and payroll software solutions, with a 14.8% revenue growth rate and a 22.2 P/E ratio that is supported by a $487m free cash flow, all of which suggest a strong and persistent growth trajectory, and it all hinges on the company's ability to maintain its 16.1% profit margin.
Moat. Paylocity's durable edge is rooted in its comprehensive suite of human capital management solutions, including payroll, HR, time and attendance, and talent management, which creates a sticky customer base due to the high switching costs associated with changing payroll and HR systems, and its 21.9% ROE is a testament to its pricing power and category leadership in the cloud-based HCM space.
Risk. The bear case against Paylocity centers on its 0.78 PEG ratio, which may indicate that the stock is overvalued given its growth prospects, and the company's 0.11 debt-to-equity ratio, while low, could become a concern if the company takes on more debt to fuel its growth, and a concrete signal that would confirm the bear case would be a significant decline in its 14.8% revenue growth rate.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 89.1
Biotechnology · price $8.70 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
1Y -51% D · Rev +19.6% B+ · ROE 42.4% A · FCF $108m C
Why now. The bull case for ADMA Biologics, Inc. rests on its ability to compound growth through its specialty plasma-derived biologics, particularly with products like BIVIGAM and ASCENIV, which treat primary humoral immunodeficiency, with a 32.4% profit margin, 19.6% revenue growth, and $108m in free cash flow, all of which suggest a strong foundation for persistent growth, hinging on the company's ability to maintain its current profit margins and revenue growth trajectory.
Moat. ADMA's durable edge is rooted in its high 42.4% ROE, which is driven by its pricing power in the niche market of plasma-derived biologics, particularly with its IVIG products, and its ability to maintain a 1.11 debt-to-equity ratio, indicating a manageable leverage that supports its growth without overextending its financials, making it challenging for competitors to quickly replicate its business model and profitability.
Risk. The bear case against ADMA highlights the risk of increased competition in the biologics market, potentially threatening its $2.0b market cap, and the company's reliance on a few key products, with a 0.73 beta indicating some sensitivity to market volatility, and a 12.8 P/E ratio that, while not excessively high, could contract if growth expectations diminish, signaling a potential downturn if ADMA fails to expand its product portfolio or maintain its market share.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. NBIX — Neurocrine Biosciences, Inc. · score 87.5
Drug Manufacturers - Specialty & Generic · price $166.06 · 1Y $194.38 · 5Y $284.59 · 10Y $422.17
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 25.5x B · PEG 0.46 A
Why now. The bull case for NBIX rests on its ability to compound growth through its portfolio of pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders, particularly with products like INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, driven by a 21.4% revenue growth rate, a 25.5 P/E ratio indicating strong earnings, and a 0.46 PEG ratio suggesting this growth is undervalued. This growth persistence is crucial as it underpins the long-term thesis.
Moat. NBIX's durable edge stems from its specific product lines like Orilissa tablets for endometriosis and Oriahnn capsules for uterine fibroids, which contribute to its 21.6% profit margin and 19.6% ROE. This profitability is attributed to pricing power from category leadership in these niche areas, which competitors cannot quickly replicate due to the high barriers to entry in pharmaceutical development and the loyalty of patients and prescribers to effective treatments.
Risk. The bear case against NBIX is centered on its dependence on a few key products and the potential for competition or regulatory challenges, particularly in the areas of endometriosis and uterine fibroids treatment, which could lead to margin contraction. With a 0.14 debt-to-equity ratio, the company has room to maneuver but a significant increase in competition or a failure in its pipeline could lead to a reevaluation of its 25.5 P/E ratio, potentially breaking the bull thesis if the company fails to deliver on its growth promises.
Horizon. 1-3 yr $194.38 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $284.59 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $422.17 if current growth sustains into durable earnings power.
9. NUTX — Nutex Health Inc. · score 87.3
Medical Care Facilities · price $147.54 · 1Y $235.50 · 5Y $344.80 · 10Y $511.48
1Y +22% B+ · Rev +82.4% A · ROE 27.8% A- · FCF $269m C
Why now. The bull case for NUTX rests on its explosive 82.4% revenue growth, driven by its Hospital segment, which offers a range of healthcare services including emergency room care, inpatient care, and behavioural health, supported by a $1.0b market cap and a 10.8 P/E ratio, all of which position the company for sustained compounding as it expands its network of micro hospitals, specialty hospitals, and hospital outpatient departments, ultimately hinging on the company's ability to maintain its 11% profit margin.
Moat. NUTX's durable edge stems from its Population Health Management (PHM) segment, which provides management, administrative, and other support services to its affiliated hospitals and physician groups, creating a network effect that enhances the stickiness of its hospital network and fuels its 27.8% ROE through pricing power from category leadership in healthcare services, a mechanism that competitors can't quickly replicate due to the complexity and integration required in healthcare operations.
Risk. The bear case against NUTX is rooted in its high 2.06 beta, signaling significant volatility, and its 0.79 debt-to-equity ratio, which, although manageable, could become a burden if the company's growth decelerates, a scenario that would be confirmed if the company's revenue growth begins to contract, breaking the bull thesis and potentially sending the stock price downward, especially if it falls below the $175 lower end of the analyst target range.
Horizon. 1-3 yr $235.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $344.80 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
10. NVDA — NVIDIA Corporation · score 86.3
Semiconductors · price $199.00 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
1Y +30% B+ · Rev +65.5% A · ROE >100% A · FCF $119.1b A
Why now. The bull case for NVDA rests on its dominance in the data center scale AI infrastructure market, driven by its Compute & Networking segment, which has delivered a 65.5% revenue growth rate FY YoY, with a 63% profit margin and $119.1b in free cash flow TTM, positioning the company for sustained compounding with a 0.64 PEG ratio.
Moat. NVIDIA's durable edge stems from its pricing power in the category leadership of data center accelerated computing and networking platforms, with an 81.7% ROE driven by its high-margin GeForce GPUs for gaming and PCs, and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics, making it difficult for competitors to replicate its business model quickly.
Risk. The bear case against NVDA centers on its high valuation, with a 30.5 P/E TTM and $4.8T market cap, leaving limited room for error, and a 2.2 beta indicating high volatility, which could be exacerbated by a downturn in the gaming or data center markets, potentially confirming the bear case if NVDA's revenue growth decelerates significantly.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
11. EXLS — ExlService Holdings, Inc. · score 86.2
Information Technology Services · price $26.34 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.8x A- · PEG 0.82 B+
Why now. The bull case for EXLS rests on its ability to compound growth through its digital operations and solutions and analytics-driven services, particularly in the Insurance and Healthcare and Life Sciences segments, with a 13.6% revenue growth rate, a 16.8 P/E ratio, and a 0.82 PEG ratio, all of which suggest a strong and sustainable growth trajectory, and the crux of this thesis is that EXLS can maintain its 11.7% profit margin.
Moat. EXLS's durable edge is its ability to provide actuarial and risk analytics, policy research, and underwriting support, which creates a switching cost for its clients and protects its 32.3% ROE, driven by pricing power from its category leadership in the Insurance and Healthcare and Life Sciences segments, making it difficult for competitors to replicate its services and margins.
Risk. The bear case against EXLS is that its 0.67 debt-to-equity ratio and 0.82 beta may indicate a higher risk profile, and if the company's revenue growth decelerates or its profit margin contracts, the stock could be vulnerable to a correction, with a concrete signal being a decline in its 13.6% revenue growth rate.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
12. FISV — Fiserv, Inc. · score 85.3
Sector n/a · price $48.19 · 1Y $70.00 · 5Y $102.49 · 10Y $152.03
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.2x A- · PEG n/a
Why now. Fiserv's high-quality compounding is driven by its 9.3% revenue growth, $4.1b in free cash flow, and a 19.7% profit margin, making it an attractive growth investment. This growth is expected to persist, driven by the company's ability to generate significant cash flow and invest in its business. The crux of this thesis rests on the company's ability to maintain its high profit margins and continue to grow its revenue.
Moat. Fiserv's durable edge is its ability to generate high returns on equity, with an 12.2% ROE, driven by its pricing power and efficient operations. This is due to its strong position in the market, allowing it to maintain high profit margins and invest in its business. A competitor would struggle to replicate this advantage quickly, given the company's established customer base and significant scale.
Risk. The bear case against Fiserv is that its stock price could be impacted by a decline in its revenue growth rate, with the company's week 52 low of $47.04 indicating potential downside risk. If the company's revenue growth were to slow significantly, its stock price could decline, confirming the bear case. This risk is mitigated by the company's diversified revenue streams and significant cash flow generation.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $102.49 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $152.03 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 85
Auto & Truck Dealerships · price $31.20 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 16.4x B+ · PEG 0.91 B+
Why now. CarGurus, Inc. is a compelling growth investment due to its ability to compound revenue growth through its online automotive platform, specifically its Digital Deal product, which has driven 13.7% revenue growth year-over-year, supported by a 15.9% profit margin and $293m in free cash flow, all while maintaining a 0.91 PEG ratio, indicating the growth is reasonably priced.
Moat. The company's durable edge is rooted in its extensive network of dealers and car shoppers, creating a network effect that protects its market position, as evidenced by its 62.9% return on equity, which is driven by pricing power from its category leadership in the online automotive marketplace.
Risk. The primary risk to the bull case is the company's dependence on dealer subscription fees, which could be disrupted by changes in the automotive market or competition from other online platforms, potentially contracting 15.9% profit margins or increasing the 0.79 debt-to-equity ratio, and if the $37.38 analyst consensus 1-yr target is missed, it could confirm the bear case.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 84.4
Information Technology Services · price $130.47 · 1Y $166.54 · 5Y $243.83 · 10Y $361.70
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 12.9x A- · PEG 0.51 A-
Why now. The bull case for Gartner, Inc. rests on its ability to compound growth through its Insights segment, which delivers high-margin, subscription-based research and advisory services, with a profit margin of 11.4%, a PEG ratio of 0.51, and revenue growth of 3.7% year-over-year, all of which position the company for sustained expansion, hinging on its capacity to maintain pricing power and continue to attract and retain high-value clients.
Moat. Gartner's durable edge stems from its Conferences segment, which offers unique networking opportunities and access to a network of business and technology experts, creating switching costs for clients who value these connections and the insights gained from them, while its Research segment provides data, benchmarks, and direct access to experts, making it a one-stop-shop for organizations seeking to inform their mission-critical priorities, thus fostering loyalty and repeat business.
Risk. The bear case against Gartner, Inc. centers on the potential for decelerating revenue growth, as evidenced by its current revenue growth of 3.7%, which, although positive, may not be sufficient to justify its current valuation, particularly if the company fails to expand its margins or if its client base becomes more price-sensitive, leading to a contraction in its profit margin of 11.4%, a scenario that would be confirmed if the company misses its revenue growth targets or reports declining profitability.
Horizon. 1-3 yr $166.54 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $243.83 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $361.70 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 83.8
Information Technology Services · price $78.39 · 1Y $144.06 · 5Y $210.91 · 10Y $312.87
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.3x A · PEG 0.39 A
Why now. The bull case for EPAM Systems, Inc. rests on its ability to compound growth through its digital platform engineering and software development services, with a 15.4% revenue growth rate and a 0.39 PEG ratio indicating undervalued growth, all while maintaining a 7% profit margin. This growth is driven by its engineering services, including requirements analysis and platform selection, customization, cross-platform migration, implementation, and integration. The crux of this thesis is that EPAM can sustain this growth rate, driven by its cloud services and data, analytics, and artificial intelligence offerings.
Moat. EPAM's durable edge is its ability to provide integrated engineering practices and smart automation services, which creates a switching cost for its clients. Additionally, its 11.3% ROE is a result of its pricing power in the digital platform engineering and software development market, where it has established itself as a leader. This edge is further reinforced by its low 0.08 debt-to-equity ratio, allowing it to invest in its business without significant financial burden.
Risk. The bear case against EPAM is that its high 1.4 beta indicates a higher volatility than the market, and its 73.06 52-week low shows that the stock can be sensitive to market downturns. Furthermore, if EPAM's revenue growth rate were to slow down significantly, its valuation multiples could contract, posing a risk to the bull thesis. A concrete signal that would confirm the bear case is if EPAM's revenue growth rate were to drop below 5% for two consecutive quarters.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $210.91 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $312.87 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 83.4
Health Information Services · price $161.35 · 1Y $245.48 · 5Y $359.41 · 10Y $533.16
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 28.6x B · PEG 0.69 A-
Why now. Veeva Systems Inc. is a compelling growth investment due to its strong position in the life sciences industry, driven by products like Veeva Commercial Cloud and Veeva Data Cloud, with a 28.6 P/E ratio, 16.3% revenue growth, and $1.7b in free cash flow, all of which suggest a high-quality compounder that can persist, resting on its ability to maintain a 28.4% profit margin.
Moat. The company's durable edge comes from its Veeva Vault CRM Suite and Veeva Medical, which provide a source of medical content and customer reference data solutions, resulting in a 12.9% ROE, driven by pricing power from category leadership in cloud-based software for the life sciences industry, making it difficult for competitors to quickly replicate its offerings.
Risk. The strongest argument against Veeva Systems Inc. is the potential for decelerating growth, as indicated by its 0.69 PEG ratio, which may suggest that the current growth rate is already priced in, and a 0.95 beta, which implies that the stock's volatility is closely tied to the overall market, making it vulnerable to market downturns, with a concrete signal being a decline in 16.3% revenue growth.
Horizon. 1-3 yr $245.48 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $359.41 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $533.16 if current growth sustains into durable earnings power.
17. DXCM — DexCom, Inc. · score 83
Medical Devices · price $69.75 · 1Y $85.21 · 5Y $124.75 · 10Y $185.06
1Y -19% D · Rev +15.6% B+ · ROE 31.5% A · FCF $1.4b C+
Why now. The bull case for DXCM rests on its ability to compound growth through its continuous glucose monitoring (CGM) systems, specifically the Dexcom G7 and G7 15 Day, with a 15.6% revenue growth rate and a 19.3% profit margin, driven by its $1.4B in free cash flow, which persists due to its strong market position and high return on equity of 31.5%.
Moat. DXCM's durable edge is its integrated CGM system, including the Dexcom G7 and G6, which provides a high switching cost for its customers, as well as its remote monitoring system, Dexcom Share, and its cost advantage in manufacturing biosensors, such as Stelo, allowing it to maintain its pricing power and high return on equity through category leadership in CGM systems.
Risk. The bear case for DXCM is that its high 29.9 P/E ratio and 1.29 PEG ratio may not be justified if its revenue growth decelerates, and its high 1.44 beta indicates a high level of market risk, which could be confirmed if the company's profit margin contracts or its debt-to-equity ratio increases, signaling a potential downturn in its business.
Horizon. 1-3 yr $85.21 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $124.75 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $185.06 if current growth sustains into durable earnings power.
18. RMD — ResMed Inc. · score 82.7
Medical Instruments & Supplies · price $196.50 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
1Y -26% D · Rev +9.8% B · ROE 23.4% A- · FCF $1.8b C+
Why now. ResMed's bull case rests on its ability to compound growth through its Sleep and Breathing Health segment, driven by products like ApneaLink Air and NightOwl, with a 27.4% profit margin, 9.8% revenue growth, and $1.8b in free cash flow, all of which suggest a strong and persistent growth trajectory, hinging on the company's ability to maintain its 18.9 P/E ratio and 1.11 PEG ratio.
Moat. ResMed's durable edge stems from its category leadership in sleep apnea diagnosis and treatment, with products like ApneaLink Air offering a unique combination of portability and diagnostic capability, which, combined with its 23.4% ROE, suggests pricing power and a cost advantage that competitors can't quickly replicate, particularly given the company's low 0.13 debt-to-equity ratio.
Risk. The bear case against ResMed centers on its valuation, with a $28.5b market cap and 18.9 P/E ratio that may be elevated, especially if revenue growth decelerates, and the company's 0.78 beta suggests some sensitivity to market volatility, with a concrete signal of trouble being a decline in 27.4% profit margin or a rise in 0.13 debt-to-equity ratio, which would undermine the bull thesis.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
19. META — Meta Platforms, Inc. · score 82.3
Internet Content & Information · price $557.67 · 1Y $827.32 · 5Y $1,211 · 10Y $1,797
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 20.3x B · PEG 0.81 B+
Why now. The bull case for META rests on its ability to compound growth through its Family of Apps (FoA) segment, which includes Facebook, Instagram, and Messenger, with a 22.2% revenue growth rate and a 20.3 P/E ratio that is reasonable for a growth name, driven by a 32.8% profit margin. This growth is likely to persist due to the strong engagement on its platforms. The crux of this thesis is that META can continue to monetize its large user base effectively.
Moat. META's durable edge comes from its strong network effects across its platforms, particularly Facebook and Instagram, which creates a self-reinforcing cycle of user engagement and advertiser demand. The 29% ROE is a testament to the pricing power that comes with category leadership in social media, which is difficult for competitors to replicate quickly.
Risk. The bear case against META is centered around its high debt-to-equity ratio of 0.36 and a 1.23 beta, which indicates a higher volatility compared to the market. If the company fails to manage its debt and navigate the evolving regulatory landscape effectively, it could lead to a contraction in its profit margin, which would break the bull thesis. A concrete signal of this would be a significant decline in its 32.8% profit margin.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $1,211 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,797 if current growth sustains into durable earnings power.
20. YELP — Yelp Inc. · score 82.2
Internet Content & Information · price $23.36 · 1Y $26.50 · 5Y $38.80 · 10Y $57.56
FCF $281m C · Rev +3.7% C+ · D/E 0.25 A- · P/E 10.7x A- · PEG 0.57 A-
Why now. The bull case for YELP rests on its ability to compound growth through its cost-per-click advertising and multi-location Ad products, with a 10.7 P/E ratio, 0.57 PEG ratio, and $281m in free cash flow, indicating a strong and undervalued franchise. The thesis ties to Yelp's 3.7% revenue growth, which persists due to its diverse platform covering various categories. The crux is whether Yelp can maintain its 9.5% profit margin, which is crucial for the bull case.
Moat. Yelp's durable edge stems from its RepairPal network and business listing pages, providing a unique value proposition to local businesses. The 22% ROE is attributed to pricing power from category leadership in the local business advertising space, which is difficult for competitors to replicate quickly. This moat is further reinforced by Yelp's low 0.25 debt-to-equity ratio, allowing for flexibility in its operations.
Risk. The bear case against YELP is centered around its dependence on the local advertising market, which may be subject to cyclical fluctuations. With a 0.47 beta, Yelp's stock price may be more volatile than the overall market. The bear case gains traction if Yelp's 3.7% revenue growth decelerates further, which could be confirmed by a decline in its $281m free cash flow, signaling a potential breakdown in the bull thesis.
Horizon. 1-3 yr $26.50 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $38.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $57.56 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 82.1
Internet Retail · price $1659.57 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
1Y -38% D · Rev +34.3% A · ROE 26.4% A- · FCF $11.8b A-
Why now. MercadoLibre's growth trajectory is propelled by its 34.3% revenue growth, driven by the expansion of its Mercado Libre Marketplace and Mercado Pago financial technology solution, with a 43.8 P/E ratio indicating investors' confidence in its prospects, and a 0.98 PEG ratio suggesting the stock is fairly valued given its growth rate. The crux of this thesis rests on the company's ability to maintain its revenue growth momentum, driven by the increasing adoption of e-commerce and digital payments in its core markets. With a $11.8B free cash flow, MercadoLibre has the resources to invest in its platforms and drive further growth.
Moat. MercadoLibre's durable edge is rooted in its Mercado Pago platform, which offers a comprehensive set of financial technology services, creating a network effect that attracts more users and merchants to its ecosystem. The company's 26.4% ROE is a testament to its pricing power, driven by its category leadership in e-commerce and digital payments. This moat is further reinforced by the switching costs associated with its Mercado Fondo and Mercado Credito services, making it difficult for competitors to replicate its business model.
Risk. The bear case against MercadoLibre is centered on its 1.7 debt-to-equity ratio, which may limit its ability to invest in new opportunities or weather economic downturns. Additionally, the company's 1.35 beta indicates a higher level of volatility, making it more susceptible to market fluctuations. If MercadoLibre's revenue growth decelerates or its profit margins contract, it could confirm the bear case and break the bull thesis, particularly if the company's $84.1B market capitalization is not supported by its underlying fundamentals.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
22. CVSA — Covista Inc. · score 82
Education & Training Services · price $122.81 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 17.9x B · PEG 0.88 B+
Why now. Covista Inc. is a compelling growth compounder due to its strong position in the healthcare education sector, particularly through its Chamberlain and Walden University segments, with a 12.9% revenue growth rate and a 17.9 P/E ratio that is reasonable for its growth profile, supported by a 0.88 PEG ratio indicating the stock is fairly valued given its growth prospects.
Moat. Covista's durable edge stems from its established presence in the healthcare education sector, with a strong portfolio of degree and non-degree programs, including nursing, health professions, and medical postsecondary education, which creates switching costs for students and provides a cost advantage through its existing infrastructure and brand recognition, as evidenced by its 17.2% ROE, driven by pricing power from category leadership in healthcare education.
Risk. The bear case against Covista centers on its debt-to-equity ratio of 0.54, which, although manageable, could become a concern if interest rates rise significantly, and the company's beta of 0.62 indicates a relatively low volatility compared to the market, but a potential downturn in the education sector or increased competition could negatively impact the stock, with a confirmation signal being a decline in revenue growth or an increase in debt levels.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
23. PRDO — Perdoceo Education Corporation · score 81.4
Education & Training Services · price $32.89 · 1Y $37.82 · 5Y $55.38 · 10Y $82.15
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.6x A- · PEG 0.70 A-
Why now. The bull case for Perdoceo Education Corporation rests on its ability to compound growth through its career-oriented disciplines, particularly in the CTU segment, with a 24.2% revenue growth rate, a 12.6 P/E ratio, and a 0.7 PEG ratio, indicating the company's growth is reasonably priced. This growth is driven by its online, campus-based, and blended learning programs, which provide a competitive edge. The crux of this thesis is the persistence of this growth, driven by the demand for postsecondary education in career-oriented fields.
Moat. Perdoceo Education Corporation's durable edge lies in its established segments, such as Colorado Technical University (CTU) and The American InterContinental University System (AIUS), which offer a range of academic programs in in-demand fields. The company's 19.9% profit margin and 17% ROE are testaments to its pricing power and efficiency, likely due to its category leadership in career-oriented education. This advantage is difficult for competitors to replicate quickly, given the resources and brand recognition required to establish similar programs.
Risk. The bear case against Perdoceo Education Corporation is rooted in its debt-to-equity ratio of 0.12 and its reliance on a few key segments, which could be vulnerable to changes in demand or regulatory pressures. If the company fails to adapt to shifting market needs or faces increased competition, its growth could decelerate, and its valuation could contract. A concrete signal that would confirm this bear case is a decline in revenue growth or a significant increase in debt levels, which would undermine the bull thesis.
Horizon. 1-3 yr $37.82 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $55.38 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $82.15 if current growth sustains into durable earnings power.
24. EPAC — Enerpac Tool Group Corp. · score 79.5
Specialty Industrial Machinery · price $36.41 · 1Y $41.87 · 5Y $61.30 · 10Y $90.94
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 22.9x B+ · PEG 0.34 A
Why now. The bull case for EPAC rests on its ability to compound growth through its highly engineered heavy lifting technology solutions, with a peg ratio of 0.34 indicating undervaluation given its 4.6% revenue growth and 13.7% profit margin. This growth persistence is driven by the company's presence in the infrastructure, industrial maintenance, and oil and gas markets. The crux of this thesis is that EPAC's $111m in free cash flow will continue to fuel its expansion into new markets and segments, such as alternative and renewable energy.
Moat. EPAC's durable edge stems from its branded hydraulic and mechanical tools, as well as its highly engineered heavy lifting technology solutions, which provide a cost advantage and switching costs for its customers. The company's 21% ROE can be attributed to its pricing power from category leadership in the industrial maintenance and repair and operations market, making it difficult for competitors to quickly replicate its offerings.
Risk. The bear case against EPAC centers on its debt-to-equity ratio of 0.46, which, although not excessively high, could become a concern if the company's growth slows and it struggles to service its debt. Additionally, the 22.9 P/E ratio might be considered elevated, especially if the company's revenue growth decelerates. A concrete signal that would confirm the bear case is a significant decline in EPAC's 4.6% revenue growth, which would put pressure on its profitability and ability to pay down debt.
Horizon. 1-3 yr $41.87 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $61.30 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $90.94 if current growth sustains into durable earnings power.
25. FIVE — Five Below, Inc. · score 79
Specialty Retail · price $187.75 · 1Y $261.57 · 5Y $382.97 · 10Y $568.11
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.7x B · PEG 0.98 B+
Why now. The bull case for Five Below, Inc. rests on its ability to compound growth through its unique assortment of products, including classic and novelty candy bars, movie-size box candy, and seasonal-related candy, which drives a 22.9% revenue growth rate, a 23.7 P/E ratio, and a 0.98 PEG ratio, all of which suggest the market is pricing in continued expansion, and the crux is whether the company can maintain its 8.7% profit margin,
Moat. Five Below's durable edge stems from its category leadership in specialty value retail, particularly in the candy, snack food, and personal care segments, where its 19% ROE suggests pricing power, which is further reinforced by its ability to maintain a 0.86 debt-to-equity ratio, allowing for strategic investments in high-return projects, and its wide range of products creates a network effect that makes it hard for competitors to replicate its offerings
Risk. The bear case against Five Below centers on its dependence on a few key product categories, such as candy and snacks, which could be disrupted by changing consumer preferences or new entrants, and the company's 0.97 beta suggests it may be more volatile than the broader market, with a potential signal to confirm the bear case being a decline in 8.7% profit margin or a rise in 0.86 debt-to-equity ratio, which could indicate that the company is struggling to maintain its competitive position
Horizon. 1-3 yr $261.57 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $382.97 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $568.11 if current growth sustains into durable earnings power.
26. HURN — Huron Consulting Group Inc. · score 78.1
Consulting Services · price $96.53 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
1Y -28% D · Rev +11.7% B · ROE 26.1% A- · FCF $124m C
Why now. The bull case for HURN rests on its ability to compound growth through its Healthcare, Education, and Commercial segments, driven by its digital services and financial and operational performance improvement consulting. With a revenue growth rate of 11.7%, a PEG ratio of 1.47, and a profit margin of 5.9%, HURN is well-positioned to continue delivering strong results. The crux of this thesis is that HURN's 26.1% ROE will persist, driven by its expertise in areas like enterprise health record and technology managed services.
Moat. HURN's durable edge is its expertise in digital services, particularly in the Healthcare segment, where it provides technology managed services and enterprise health record solutions. This expertise, combined with its 26.1% ROE, driven by pricing power from category leadership in these areas, creates a moat that protects its growth. Competitors cannot quickly replicate HURN's expertise and relationships in these areas, allowing it to maintain its market position.
Risk. The bear case for HURN centers on its high debt-to-equity ratio of 2.24, which could become a significant burden if interest rates rise or the company's growth slows. Additionally, the PEG ratio of 1.47 is slightly above 1, indicating that the stock may be overvalued relative to its growth rate. If HURN's revenue growth rate were to slow significantly, the stock could be at risk of a sharp decline, confirming the bear case.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
27. WLDN — Willdan Group, Inc. · score 77.9
Engineering & Construction · price $80.73 · 1Y $92.84 · 5Y $135.93 · 10Y $201.64
FCF $43m C- · Rev +20.5% A- · D/E 0.22 A- · P/E 21.7x B+ · PEG 0.48 A
Why now. The bull case for WLDN rests on its ability to compound growth through its Energy segment, which offers comprehensive audit and surveys, program design and implementation, and software and data analytics, with a 20.5% revenue growth rate and a $1.2b market cap. This growth is further supported by a 21.7 P/E ratio and a 0.48 PEG ratio, indicating that the company's growth is reasonably priced. The crux of this thesis is that WLDN's 8.2% profit margin will persist, driven by its Energy segment's high-margin services.
Moat. WLDN's durable edge is its expertise in energy auditing and consulting, which creates switching costs for its customers and prevents competitors from easily replicating its services. The company's 18.2% ROE is a result of its pricing power in the energy consulting market, where it can command high margins for its specialized services. This edge is further reinforced by WLDN's $43m in free cash flow, which it can use to invest in its business and maintain its competitive position.
Risk. The bear case for WLDN is that its 1.11 beta and 0.22 debt-to-equity ratio make it vulnerable to market downturns and interest rate increases. If the company's revenue growth slows, its 21.7 P/E ratio may become unsustainable, leading to a decline in the stock price. A concrete signal that would confirm the bear case is if WLDN's revenue growth rate were to fall below 10%, indicating that the company's Energy segment is losing momentum.
Horizon. 1-3 yr $92.84 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $135.93 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $201.64 if current growth sustains into durable earnings power.
28. DV — DoubleVerify Holdings, Inc. · score 77.7
Advertising Agencies · price $10.35 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
1Y -29% D · Rev +13.9% B+ · ROE 5.1% C+ · FCF $135m C
Why now. The bull case for DoubleVerify Holdings, Inc. rests on its ability to compound growth through its media effectiveness platforms, specifically the DV Authentic Ad and Custom Contextual solution, which drive campaign performance and maximize user engagement. With a revenue growth rate of 13.9%, a PEG ratio of 0.61, and a profit margin of 7.2%, the company is well-positioned for sustained growth. The crux of this thesis is the persistence of this compounding, driven by the stickiness of its solutions and the expanding demand for digital media quality measurement.
Moat. DoubleVerify's durable edge stems from its Scibids AI and Rockerbox solutions, which provide unparalleled campaign optimization and cross-channel conversion insights. The company's ROE of 5.1% is a testament to its ability to generate returns from its investments in these technologies. Furthermore, the switching costs associated with adopting DoubleVerify's platforms, combined with the network effects of its growing customer base, make it difficult for competitors to replicate its offerings quickly.
Risk. The bear case against DoubleVerify centers on the potential for debt to equity ratio of 0.09 to increase, which could strain the company's balance sheet and limit its ability to invest in growth initiatives. Additionally, the analyst consensus 1-yr target range of $8-$16 suggests that there is some uncertainty around the company's short-term prospects. A concrete signal that would confirm the bear case is a significant deceleration in revenue growth, which would undermine the bull thesis and suggest that DoubleVerify's compounding growth story is at risk.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
29. APP — AppLovin Corporation · score 77.5
Advertising Agencies · price $464.96 · 1Y $650.30 · 5Y $952.10 · 10Y $1,412
1Y +38% B+ · Rev +70.0% A · ROE >100% A · FCF $4.4b B
Why now. The bull case for AppLovin Corporation rests on its ability to compound growth through its artificial intelligence-powered advertising solutions, specifically its Axon Ads Manager and MAX in-app bidding technology, with a 70% revenue growth rate, a 40.5 P/E ratio, and a $4.4B free cash flow, all of which position the company for sustained expansion in the advertising sector. This growth is further supported by its 64.3% profit margin, indicating efficient operations. The crux of this thesis is the persistence of this high growth rate, driven by the increasing demand for AI-powered advertising solutions.
Moat. AppLovin's durable edge is rooted in its Adjust measurement and analytics marketing platform, which provides a high degree of specificity and accuracy in marketing efforts, creating a switching cost for its customers. Additionally, its Wurl connected TV platform offers a unique distribution channel for streaming video content, providing a cost advantage in reaching a targeted audience. This combination of specific product offerings and segment expertise creates a barrier to entry for competitors, protecting AppLovin's market position.
Risk. The bear case against AppLovin centers on its high debt-to-equity ratio of 1.63 and its elevated P/E ratio of 40.5, which may indicate overvaluation. Furthermore, the company's high beta of 2.46 suggests a significant level of market volatility, making it susceptible to broader market fluctuations. A concrete signal that would confirm the bear case is a significant decline in revenue growth, potentially triggered by increased competition in the AI-powered advertising space or a shift in consumer behavior away from the platforms AppLovin serves.
Horizon. 1-3 yr $650.30 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $952.10 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,412 if current growth sustains into durable earnings power.
30. DECK — Deckers Outdoor Corporation · score 77.5
Footwear & Accessories · price $105.70 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
1Y +3% C+ · Rev +9.8% B · ROE 41.0% A · FCF $1.1b C+
Why now. The bull case for DECK rests on its ability to compound growth through its high-performance footwear brands, particularly HOKA, which drives a 9.8% revenue growth rate, a 15.1 P/E ratio, and a 41% ROE. This growth is further supported by the company's strong profit margin of 18.7% and its low debt-to-equity ratio of 0.15. The crux of this thesis is that DECK's portfolio of brands will continue to drive growth and profitability, fueled by the increasing demand for high-performance and casual lifestyle footwear.
Moat. DECK's durable competitive advantage lies in its portfolio of strong brands, including UGG, HOKA, and Teva, which have built significant customer loyalty and recognition. The company's ability to maintain a high ROE of 41% is attributed to its pricing power, driven by its category leadership in the high-performance and casual lifestyle footwear markets. This pricing power, combined with its efficient distribution network and strong brand recognition, makes it difficult for competitors to quickly replicate DECK's success.
Risk. The bear case against DECK is centered around its reliance on a few key brands and the potential for a decline in demand for high-performance and casual lifestyle footwear. With a 1.31 PEG ratio and a 1.15 beta, the stock may be vulnerable to market volatility and a potential downturn in the footwear industry. If DECK's revenue growth rate were to slow significantly, it could confirm the bear case and break the bull thesis, making the current valuation of $14.7b and $105.7 per share less sustainable.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.